On Monday the FDA approved Bayer’s Sunharbo for reducing recurrent stroke, the first drug in a class that inhibits Factor XIa and is meant to limit clots without the bleeding risk that keeps many thinners out of this setting. In phase 3 among patients who had already had a stroke, secondary stroke h